Javier de laSerna

8PUBLICATIONS
72CO-AUTHORS
Medical infection agents (incl. prions)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 01, 2025
Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review.

Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Jorge Boán

|Jan 12, 2023
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton

|Dec 24, 2022
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton

|May 23, 2022
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

John F Seymour, Thomas J Kipps, Barbara F Eichhorst

|Sep 10, 2021
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

Julia González-Rincón, José A Garcia-Vela, Sagrario Gómez

|Sep 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

Arnon P Kater, Jenny Qun Wu, Thomas Kipps

Pageof 2

Frequent Collaborators

2 joint publications

Birna Thorvaldsdottir

2 joint publications

Christian Brieghel

2 joint publications

Marta Sobas

2 joint publications

John F Seymour